Andrew Olsen

Andrew Olsen, Ph.D. is an experienced professional in business development and scientific analysis, currently serving as Associate Director of Business Development at Actinium Pharmaceuticals, Inc. since September 2021, and previously held roles including Business Development Manager and Senior Associate in Scientific and Business Analysis at the same company. Prior to this, Andrew worked at Prescient Healthcare Group, focusing on competitive intelligence in oncology and other fields, and co-founded Brooklyn BioScience, which develops protein-based technology for pesticide degradation. Andrew's research background includes a Doctor of Philosophy in Materials Chemistry from New York University, and significant contributions during academic tenure, including grant applications and publications in biotechnology and bioengineering. Andrew's earlier experience includes an internship in environmental engineering and various roles in academic support and research at the University of Maryland.